SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim DH who wrote (3682)	8/12/1998 9:25:00 AM
From: dwlima	Read Replies (1) of 5402

Northfield Laboratories (a development stage company) is engaged in the development of an alternative to transfused blood for use in the treatment of acute blood loss. For the nine months ended 2/28/98, the Company reported no revenues. Net loss increased 31% to $4.2 million. Results reflect increased R&D expenses related to the Phase III clinical trials. Results also reflect increased S/G/A costs due to higher travel and professional services expenses. Big losses, no revenues and a market cap of $250 million. well, if we were in phase 3 with a product and had the same market cap, we would have a stock price of $12.50. upside is huge and downside seems to be limited at this point as i think there is always a 30-cent (or few million dollar value) until we see test results. just my opinion dwlima

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next